相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1892
已完成
2
100.0%
暂无批准数据
- Several high-profile federal health initiatives rely on voluntary industry agreements rather than regulation, and reporting finds the promised changes have largely not arrived on the announced timelines. - The FDA quietly moved its synthetic dye removal deadline from the end of 2026 to the end of 2027, with fewer than 30% of pledged companies meeting their goals. - Health plans reduced prior authorization for medical services by only about 11% as of July, far short of the announced January 2026 target, and promised public dashboards have not launched. - Seventeen drugmakers agreed to lower prices for Medicaid enrollees and cash-paying consumers, but the deals do not cover existing drugs for the more than 200 million Americans with commercial or private coverage.
- The "protein-maxxing" trend, driven by social media and GLP-1 drug use, has pushed protein-fortified foods and supplements into the mainstream despite most people already meeting their protein needs. - Nutrition experts caution that the body can only absorb about 30 grams of protein per intake, with excess protein excreted through the kidneys or stored as fat. - People with kidney disease should be wary of high protein intake, and extreme overconsumption has led to kidney failure in some cases. - Dietitians emphasize whole foods and balanced intake of protein, carbohydrates, and fats rather than relying on protein shakes and fortified snacks.
- Coca-Cola is under investigation by the COMESA Competition Commission for potential antitrust violations related to restrictive distribution agreements. - Kenya's Competition Authority is also scrutinizing Coca-Cola for similar antitrust breaches related to distribution practices. - Espar settled for millions to avoid claims of colluding to fix vehicle parking heater prices, while Sika received conditional Phase II clearance in Peru.
